KRAS and adenocarcinoma: Most driver mutations in EGFR, TP53, and KRAS were probabilistically assigned to signatures SBS5 and SBS40a (Fig. 2g), with the proportion of driver mutations significantly higher than expected according to their prevalence in the overall adenocarcinoma cohort (OR=2.55; p-value=9.8 × 10−22; Fig. 2d).